Tags

Type your tag names separated by a space and hit enter

Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.
Int J Neuropsychopharmacol. 2010 Nov; 13(10):1343-54.IJ

Abstract

Galantamine, a drug used to treat Alzheimer's disease, inhibits acetylcholinesterase (AChE) and allosterically modulates nicotinic acetylcholine receptors (nAChRs) resulting in stimulation of catecholamine neurotransmission. In this study, we investigated whether galantamine exerts cognitive-improving effects through the allosteric modulation of nAChRs in an animal model of methamphetamine (Meth) psychosis. The mice treated with Meth (1 mg/kg.d) for 7 d showed memory impairment in a novel object recognition test. Galantamine (3 mg/kg) ameliorated the memory impairment, and it increased the extracellular dopamine release in the prefrontal cortex (PFC) of Meth-treated mice. Donepezil, an AChE inhibitor (1 mg/kg) increased the extracellular ACh release in the PFC, whereas it had no effect on the memory impairment in Meth-treated mice. The nAChR antagonist, mecamylamine, and dopamine D1 receptor antagonist, SCH 23390, blocked the ameliorating effect of galantamine on Meth-induced memory impairment, whereas the muscarinic AChR antagonist, scopolamine, had no effect. The effects of galantamine on extracellular dopamine release were also antagonized by mecamylamine. Galantamine attenuated the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2). The ameliorating effect of galantamine on recognition memory in Meth-treated mice was negated by microinjection of an ERK inhibitor, PD98059, into the PFC. These results suggest that the ameliorating effect of galantamine on Meth-induced memory impairment is associated with indirect activation of dopamine D1 receptor-ERK1/2 following augmentation with dopaminergic neurotransmission in the PFC through the allosteric activation of nAChRs. Galantamine could be a useful therapeutic agent for treating cognitive deficits in schizophrenia/Meth psychosis, as well as Alzheimer's disease.

Authors+Show Affiliations

Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, Graduate School of Pharmaceutical Science, Nagoya, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20219155

Citation

Noda, Yukihiro, et al. "Galantamine Ameliorates the Impairment of Recognition Memory in Mice Repeatedly Treated With Methamphetamine: Involvement of Allosteric Potentiation of Nicotinic Acetylcholine Receptors and dopaminergic-ERK1/2 Systems." The International Journal of Neuropsychopharmacology, vol. 13, no. 10, 2010, pp. 1343-54.
Noda Y, Mouri A, Ando Y, et al. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharmacol. 2010;13(10):1343-54.
Noda, Y., Mouri, A., Ando, Y., Waki, Y., Yamada, S. N., Yoshimi, A., Yamada, K., Ozaki, N., Wang, D., & Nabeshima, T. (2010). Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. The International Journal of Neuropsychopharmacology, 13(10), 1343-54. https://doi.org/10.1017/S1461145710000222
Noda Y, et al. Galantamine Ameliorates the Impairment of Recognition Memory in Mice Repeatedly Treated With Methamphetamine: Involvement of Allosteric Potentiation of Nicotinic Acetylcholine Receptors and dopaminergic-ERK1/2 Systems. Int J Neuropsychopharmacol. 2010;13(10):1343-54. PubMed PMID: 20219155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. AU - Noda,Yukihiro, AU - Mouri,Akihiro, AU - Ando,Yu, AU - Waki,Yukari, AU - Yamada,Shin-Nosuke, AU - Yoshimi,Akira, AU - Yamada,Kiyofumi, AU - Ozaki,Norio, AU - Wang,Dayong, AU - Nabeshima,Toshitaka, Y1 - 2010/03/11/ PY - 2010/3/12/entrez PY - 2010/3/12/pubmed PY - 2011/3/19/medline SP - 1343 EP - 54 JF - The international journal of neuropsychopharmacology JO - Int J Neuropsychopharmacol VL - 13 IS - 10 N2 - Galantamine, a drug used to treat Alzheimer's disease, inhibits acetylcholinesterase (AChE) and allosterically modulates nicotinic acetylcholine receptors (nAChRs) resulting in stimulation of catecholamine neurotransmission. In this study, we investigated whether galantamine exerts cognitive-improving effects through the allosteric modulation of nAChRs in an animal model of methamphetamine (Meth) psychosis. The mice treated with Meth (1 mg/kg.d) for 7 d showed memory impairment in a novel object recognition test. Galantamine (3 mg/kg) ameliorated the memory impairment, and it increased the extracellular dopamine release in the prefrontal cortex (PFC) of Meth-treated mice. Donepezil, an AChE inhibitor (1 mg/kg) increased the extracellular ACh release in the PFC, whereas it had no effect on the memory impairment in Meth-treated mice. The nAChR antagonist, mecamylamine, and dopamine D1 receptor antagonist, SCH 23390, blocked the ameliorating effect of galantamine on Meth-induced memory impairment, whereas the muscarinic AChR antagonist, scopolamine, had no effect. The effects of galantamine on extracellular dopamine release were also antagonized by mecamylamine. Galantamine attenuated the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2). The ameliorating effect of galantamine on recognition memory in Meth-treated mice was negated by microinjection of an ERK inhibitor, PD98059, into the PFC. These results suggest that the ameliorating effect of galantamine on Meth-induced memory impairment is associated with indirect activation of dopamine D1 receptor-ERK1/2 following augmentation with dopaminergic neurotransmission in the PFC through the allosteric activation of nAChRs. Galantamine could be a useful therapeutic agent for treating cognitive deficits in schizophrenia/Meth psychosis, as well as Alzheimer's disease. SN - 1469-5111 UR - https://www.unboundmedicine.com/medline/citation/20219155/Galantamine_ameliorates_the_impairment_of_recognition_memory_in_mice_repeatedly_treated_with_methamphetamine:_involvement_of_allosteric_potentiation_of_nicotinic_acetylcholine_receptors_and_dopaminergic_ERK1/2_systems_ L2 - https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145710000222 DB - PRIME DP - Unbound Medicine ER -